Impact of finerenone on chronic kidney disease progression in Chinese patients with type 2 diabetes: a FIGARO-DKD subgroup analysis

BackgroundType 2 diabetes (T2D) is a considerable and growing burden in the Chinese population, and affected adults are at high risk of developing chronic kidney disease (CKD). This subgroup analysis of the FIGARO-DKD trial explored the cardiovascular and kidney benefits of finerenone in Chinese pat...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ping Li, Hongguang Zheng, Jianhua Ma, Weiping Lu, Ling Li, Fang Liu, Qing Su, Yuxiu Li, Yi Fang, Zhaohui Mo, Fei Xiong, Aiping Yin, Ying Zhang, Li Wang, Meike Brinker, Luke Roberts, Dalong Zhu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-04-01
Edice:	Frontiers in Endocrinology
Témata:	Chinese patients chronic kidney disease diabetic kidney disease FIGARO-DKD finerenone type 2 diabetes
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1568438/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!